image credit: Unsplash

Pfizer/BioNTech’s COVID-19 vaccine wins first full FDA approval

August 24, 2021


In December 2020, the FDA approved an emergency use authorisation (EUA) for the Pfizer/BioNTech COVID-19 vaccine, based on preliminary data from a pivotal Phase III clinical trial.

As part of their Biologics License Application (BLA) for Comirnaty, Pfizer and BioNTech submitted a ‘comprehensive’ data package, including long-term follow-up data from the Phase III trial as well as manufacturing and facilities data.

The companies are also planning to submit an application for approval of a third booster dose of Comirnaty in individuals 16 years of age and older via a supplemental BLA.

Read More on Pharma Times